Pro-Dex, Inc. (NASDAQ:PDEX) Director Raymond E. Cabillot Sells 835 Shares

Pro-Dex, Inc. (NASDAQ:PDEX - Get Free Report) Director Raymond E. Cabillot sold 835 shares of the business's stock in a transaction dated Thursday, January 23rd. The shares were sold at an average price of $42.00, for a total transaction of $35,070.00. Following the completion of the transaction, the director now directly owns 334,646 shares of the company's stock, valued at $14,055,132. The trade was a 0.25 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Pro-Dex Trading Down 2.9 %

Shares of Pro-Dex stock traded down $1.20 during trading hours on Friday, reaching $40.66. The stock had a trading volume of 23,534 shares, compared to its average volume of 27,182. The firm has a market capitalization of $132.55 million, a price-to-earnings ratio of 26.40 and a beta of 0.56. Pro-Dex, Inc. has a 1 year low of $16.18 and a 1 year high of $59.60. The company has a current ratio of 3.41, a quick ratio of 1.94 and a debt-to-equity ratio of 0.36. The firm has a 50 day simple moving average of $47.87 and a two-hundred day simple moving average of $33.56.

Hedge Funds Weigh In On Pro-Dex

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Dimensional Fund Advisors LP boosted its position in shares of Pro-Dex by 5.1% in the second quarter. Dimensional Fund Advisors LP now owns 63,036 shares of the medical instruments supplier's stock worth $1,238,000 after buying an additional 3,067 shares during the period. Renaissance Technologies LLC boosted its holdings in Pro-Dex by 7.9% in the second quarter. Renaissance Technologies LLC now owns 12,240 shares of the medical instruments supplier's stock valued at $240,000 after purchasing an additional 900 shares during the last quarter. Bard Associates Inc. raised its holdings in Pro-Dex by 17.6% in the third quarter. Bard Associates Inc. now owns 13,596 shares of the medical instruments supplier's stock valued at $406,000 after acquiring an additional 2,031 shares in the last quarter. FMR LLC grew its stake in Pro-Dex by 34.9% in the third quarter. FMR LLC now owns 3,973 shares of the medical instruments supplier's stock worth $119,000 after purchasing an additional 1,028 shares in the last quarter. Finally, Geode Capital Management LLC lifted its holdings in Pro-Dex by 9.1% during the 3rd quarter. Geode Capital Management LLC now owns 27,435 shares of the medical instruments supplier's stock worth $819,000 after buying an additional 2,296 shares during the last quarter. Institutional investors and hedge funds own 15.28% of the company's stock.

Analysts Set New Price Targets

Several brokerages have weighed in on PDEX. StockNews.com upgraded Pro-Dex from a "buy" rating to a "strong-buy" rating in a report on Saturday, December 14th. Ascendiant Capital Markets upped their price target on shares of Pro-Dex from $30.00 to $52.00 and gave the stock a "buy" rating in a research report on Monday, November 11th.

About Pro-Dex

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.